Timber Pharmaceuticals Long Term Debt

As of the most recent data (June 2023), TMBR shows a long-term debt of $320K. That compares with $160K in the prior-year period — up 96.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TMBR's long-term debt is now $320K (was $160K) — a 96.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Timber Pharmaceuticals is outperforming or lagging.

Tracking TMBR's long-term debt over time shows whether Timber Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $320K That compares with $160K in the prior-year period — up 96.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Timber Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $320K) with ownership activity and broader fundamentals.

Timber Pharmaceuticals's long-term debt is $320K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.